Inhibikase Therapeutic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Inhibikase therapeutic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Inhibikase Therapeutic Today - Breaking & Trending Today

Inhibikase's risvodetinib wins FDA orphan drug designation - Pharmaceutical Technology

Inhibikase is planning a Phase II trial to investigate its Abelson Tyrosine Kinase inhibitor in MSA. ....

Shutterstock Andrii Vodolazhskyi , Milton Werner , Company Profiles , Company Profile , Drug Administration , Movement Disorder Society , Inhibikase Therapeutic , Abelson Tyrosine Kinase , Chief Executive , Inhibikase Therapeutics , Alterity Therapeutics ,

Pharmaceutical Technology

Pharmaceutical Technology
pharmaceutical-technology.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceutical-technology.com Daily Mail and Mail on Sunday newspapers.

Milton Werner , Drug Administration , Movement Disorder Society , Inhibikase Therapeutic , Abelson Tyrosine Kinase , Chief Executive , Inhibikase Therapeutics , Alterity Therapeutics ,

New Parkinson's drug formulation "nearly doubles" exposure

New Parkinson's drug formulation "nearly doubles" exposure
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

Milton Werner , New Parkinson , Abelson Tyrosine Kinase , Inhibikase Therapeutic , Inhibikase Therapeutics , Investigational New Drug ,

Inhibikase Therapeutics, Inc. to Post Q2 2023 Earnings of ($0.15) Per Share, HC Wainwright Forecasts (NYSE:IKT)

Inhibikase Therapeutics, Inc. (NYSE:IKT – Get Rating) – Stock analysts at HC Wainwright raised their Q2 2023 earnings per share estimates for shares of Inhibikase Therapeutics in a research report issued on Tuesday, May 16th. HC Wainwright analyst E. White now forecasts that the company will earn ($0.15) per share for the quarter, up from […] ....

Armistice Capital , Renaissance Technologies , Vanguard Group Inc , Blair William Co , Inhibikase Therapeutics Inc , Inhibikase Therapeutics , Get Rating , Inhibikase Therapeutic , Lane Advisors , Vanguard Group , Inhibikase Therapeutics Daily , Nyse Ikt , Earnings Estimates , Hc Wainwright ,

Reviewing Finch Therapeutics Group (NASDAQ:FNCH) & Inhibikase Therapeutics (NYSE:IKT)

Finch Therapeutics Group (NASDAQ:FNCH – Get Rating) and Inhibikase Therapeutics (NYSE:IKT – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk. Insider and Institutional Ownership 22.7% of Finch Therapeutics […] ....

United States , Johns Hopkins University , Inhibikase Therapeutics Inc , Inhibikase Therapeutics Company Profile Get Rating , Takeda Pharmaceutical Company , Finch Therapeutics Group , Finch Therapeutics Group Company Profile Get Rating , Finch Therapeutics Group Inc , University Of Minnesota , Memorial Sloan Kettering Cancer Center , Skysong Innovations , Louisiana State University School Of Medicine , Get Rating , Inhibikase Therapeutics , Therapeutics Group , Given Inhibikase Therapeutic , Finch Therapeutics , Inhibikase Therapeutic , Therapeutics Group Company Profile , Takeda Pharmaceutical Company Limited , Therapeutics Company Profile , Louisiana State University School , Memorial Sloan Kettering Cancer , Nasdaq Fnch , Stock Comparison , Stock Analysis ,